Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis

• Published in: The New England journal of medicine Vol. 384; no. 13; pp. 1227 - 1239
• Main Authors: McInnes, Iain B, Anderson, Jaclyn K, Magrey, Marina, Merola, Joseph F, Liu, Yi, Kishimoto, Mitsumasa, Jeka, Slawomir, Pacheco-Tena, Cesar, Wang, Xin, Chen, Liang, Zueger, Patrick, Liu, John, Pangan, Aileen L, Behrens, Frank
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 01.04.2021
• Subjects: Adalimumab - adverse effects; Adalimumab - therapeutic use; Adult; Adverse events; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - therapeutic use; Arthritis; Arthritis, Psoriatic - drug therapy; Dosage; Dose-Response Relationship, Drug; Double-Blind Method; Drug dosages; Enzyme inhibitors; Female; Heterocyclic Compounds, 3-Ring - administration & dosage; Heterocyclic Compounds, 3-Ring - adverse effects; Heterocyclic Compounds, 3-Ring - therapeutic use; Humans; Janus kinase; Janus Kinase Inhibitors - therapeutic use; Joint diseases; Least-Squares Analysis; Liver Diseases - etiology; Male; Middle Aged; Monoclonal antibodies; Pain; Patients; Placebos; Psoriasis; Psoriatic arthritis; Questionnaires; Rheumatoid arthritis; Statistical analysis; TNF inhibitors; Tumor necrosis factor-α
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa2022516

In a trial comparing the JAK inhibitor upadacitinib (15 or 30 mg daily) with placebo and with the TNF-α inhibitor adalimumab, the percentage of patients with an ACR20 response at 12 weeks was 70.6% with the 15-mg dose, 78.5% with the 30-mg dose, 36.2% with placebo, and 65.0% with adalimumab. There were hepatic disorders with upadacitinib.